Eighteen cases of resected cholangiocellular carcinoma of the liver were investigated to elucidate their clinical features in relation to the macroscopic classification. The tumors were classified into three types according to the macroscopic classification proposed by the Liver Cancer Study Group of Japan: (1) mass-forming type, growing an apparent tumor in the liver; (2) periductal infiltrating type, extending along the intrahepatic bile duct, and (3) intraductal growth type, growing into the bile duct. Abdominal pain was the most frequent symptom in the mass-forming type and the periductal infiltrating type, and fever was the more predominant symptom in the periductal infiltrating type than in the mass-forming type. Hepatolithiasis was found to coexist more frequently with the periductal infiltrating type than with the mass-forming type. A positive surgical margin was more frequently detected in the periductal infiltrating type due to its infiltrating tendency than in the mass-forming type. Two patients with the mass-forming type and 1 patient with the intraductal growth type survived more than 5 years. In conclusion, this macroscopic classification is therefore thought to be useful for both selecting the most appropriate treatment approach as well as for predicting prognosis.

Keywords:
Cholangiocellular carcinoma, Macroscopic classification, Clinical features, Prognosis
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.